|
Li Liu has served on the faculty of UT Southwestern Medical Center in the department of Radiology since 2008 after completing her Ph.D. from Nankai University in Tianjin, China, and postdoctoral fellowship training in molecular pharmacology at the Max Planck Chemical and Ecology Institute in Jena, Germany, in genetics and microbiology at the University of Florida, and in molecular imaging at UT Southwestern. Dr. Liu’s research focuses on development and application of reporter genes and molecular gene reporters for multimodality imaging, particularly related to cancer in small animal models. Dynamic imaging provides effective insight into tumor progression and response to therapy, particularly as applied to the development of vascular disputing agents in vivo. Most recently, she has explored multispectral optoacoustic tomography (MSOT) to provide real-time non-invasive insight into the vasculature of malignant tumors with respect to experimental drugs. |
|
Devin O’Kelly is a Computational Scientist at the BioHPC high-performance computing facility, located at the University of Texas Southwestern Medical Center at Dallas. He earned his Ph.D. in biomedical and molecular imaging with a supplement in computational and systems biology, developing models and methods for interpreting MSOT data in the context of dynamic vascular imaging. His primary research interests focus on improving and enabling the effective analysis of high-dimensional imaging data, as well as relating acquired data to models of the underlying biological systems. |
|
Regan J. Schuetze is a research technician in the Prognostic Imaging Research Lab. He joined the lab at UT Southwestern in 2020 after graduating from Furman University with a degree in neuroscience. His previous research investigated the role of dopamine in post-traumatic stress disorder and comorbid substance abuse and his current research represents a new interest in broader physiology. |
|
Graham J. Carlson is a Ph.D. candidate at Baylor University carrying out research under the mentorship of Dr. Pinney. He joined the Pinney Laboratory in 2014 after graduating from Hope College with a degree in chemistry. His current research focuses on the design and synthesis of new inhibitors of tubulin polymerization together with corresponding vascular disrupting agents (VDAs) and various associated prodrugs, designed to enhance selectivity, efficacy and aqueous solubility of promising lead molecules. |
|
Heling Zhou received her undergraduate degree in biomedical engineering at Sun Yet-sen University and her doctorate degree in radiological sciences at UT Southwestern Medical Center. She developed imaging analytical techniques to assess tumor microenvironment and its relationship to treatment outcomes. She is now pursuing a career as a data engineer, building scalable data management and analytics solutions, and is currently a data engineer lead in a health-tech company developing artificial intelligence for radiologists. |
|
Mary Lynn Trawick (formerly Dr. Mary Lynn Fink) is Associate Professor of Biochemistry in the Department of Chemistry and Biochemistry at Baylor University where she participates in the Institute for Biomedical Studies, the Molecular Biosciences Center, and the Center for Drug Discovery, and is a member of the Institutional Biosafety Committee. Her major research interests include the design, evaluation, and mechanism of action of novel anticancer agents with selectivity for the tumor microenvironment, and strategies to inhibit cancer metastasis. |
|
Kevin G. Pinney has served on the faculty of Baylor University in the Department of Chemistry and Biochemistry since 1993 after completing his Ph.D. at the University of Illinois, Urbana-Champaign and postdoctoral studies at the University of South Carolina. He is a Professor of Chemistry leading a dynamic research group focused on the design and synthesis of structurally diverse and biologically interesting small-molecule analogues, many of which are inspired by natural products. Well-established, diverse research projects include vascular disrupting agents (VDAs), inhibitors of tubulin polymerization, inhibitors of cathepsin L (and/or K), hypoxia-activated prodrugs and related drug-linker constructs. He teaches classes at both the undergraduate and graduate level in the area of organic chemistry. Research in his laboratory has been funded over the years by various grants from the National Institutes of Health, the Cancer Prevention and Research Institute of Texas (CPRIT), and a pharmaceutical company. He continues to enjoy productive research collaborations including those with the Mason Group (UT Southwestern Medical Center, Dallas, TX) and the Trawick Group (Baylor University). |
|
Ralph P. Mason is Professor of Radiology and Fellow of the Royal Society of Chemistry. He serves as the Director of the Small Animal Imaging Shared Resource at Simmons Comprehensive Cancer Center. He joined UT Southwestern 35 years ago after completing undergraduate and postgraduate studies at the University of Cambridge. His primary research interest is prognostic radiology: developing and implementing methods for predicting optimal cancer therapy and assessing early response to treatment (precision medicine). His particular interests have long related to prostate and breast cancer and most recently lung and kidney. He serves as advisor to graduate students in biomedical engineering and cancer biology and as mentor to postdocs and young faculty. He has been the recipient of multiple awards from the NCI and CPRIT. For 10 years, he has collaborated closely with the team at Baylor University to evaluate novel small molecule vascular disrupting agents for selective cancer treatment. |